Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...
CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...
The FDA first approved Zepbound to treat obesity in November 2023. Its active ingredient, tirzepatide, was previously ...
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).
The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...
Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback